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Harry M Marks, Theprogress of
experiment: science and therapeutic reform in
the United States, 1900-1990, Cambridge
History of Medicine, Cambridge University
Press, 1997, pp. xii, 258, £45.00, $59.95
(hardback 0-521-58142-7), £14.95, $19.95
(paperback 0-521-78561-8).
The publication of this paperback edition
of Theprogress ofexperiment is to be
warmly welcomed. Since its original
appearance in 1997, the book has become
essential reading for anyone thinking about
the place of science within twentieth-century
medicine. Harry M Marks' subject is how
Americans decided whether drugs were safe
and whether they worked, in an age when
market forces seemed to muddy such
questions. Today the randomized clinical
trial is touted as the means ofevaluating
drugs, but this was not always the case, nor
was it always certain that this measure
would prevail.
Marks' story revolves around those he
characterizes as "therapeutic reformers", a
motley group of pharmacologists,
physiologists, statisticians, clinical specialists
and others, who sought to use controlled
experiments to direct medical practice.
Concerned about the dubious claims of
unethical pharmaceutical companies for
their products, and the seeming inability of
many medical practitioners to see through
such claims, reformers looked for a solution
to the integrity ofexperienced researchers
dedicated to the ideals ofexperimental
science. To this end, they came to promote
what they called "collective investigations"
in the nineteenth century, and "cooperative
studies" or "investigations" in the 1930s and
1940s. As the names suggest, these
investigations involved a bevy of
experts-community-based physicians in the
former, university-based researchers in the
latter-collaborating to evaluate the
therapeutic effects ofdrugs. In the early
1930s, Marks notes, such studies were used
to avoid the methodological pitfalls of
relying on individually conducted research,
on idiosyncratic meanings ofdisease and
treatment, and on small case series the
conclusions ofwhich might be distorted by
the cycles of spontaneous recovery and
remission characteristic of many ills.
Before the Second World War, Marks
argues, therapeutic reformers focused on
creating institutional mechanisms for
improving therapeutic practice. Thus, in
1906 the American Medical Association
established its Council ofPharmacy and
Chemistry, which comprised a body of
experienced researchers who sought to
provide independent evaluations of drug
companies' claims about the effects of
specific therapies on disease. The US Food
and Drug Administration (FDA) adopted
the Council's methods when it became
involved in assessing the safety and efficacy
of drugs in the 1930s and 1940s. Yet, in the
end, such methods were not to survive as a
means ofregulating therapeutic practice,
and the FDA decided that it could not stop
physicians using medicines for purposes for
which they had not been approved.
If this book is a story about the
mechanisms by which reformers sought to
evaluate drugs, it is also about the ideals
embedded in such mechanisms or, more
properly, the death ofcertain ideals.
Reformers once saw science as a means of
instilling a critical attitude towards
therapeutics across the medical profession,
yet this utopian vision soon faded. The fact
that so many practitioners, although
scientifically trained, seemed to fall prey to
the marketing hype of the drugs companies
raised questions about their competence.
Differences in training and technical skill,
reformers felt, continued to divide the
profession, despite the high hopes vested in
science as a means of dissolving such
difference. Their disillusion was built into
the institutional mechanisms by which
reformers sought to assess the value of
drugs. Certain groups-university-based
physicians, government scientists and
others-gained much more say than the rest
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of the profession in deciding how drugs
were to be evaluated.
If the ideal of a profession united by
science fell by the wayside, so too did
another key element of reform ideology; the
trust placed in the high moral character of
individual clinicians to ensure the integrity
of observations on the therapeutic effects of
drugs. Marks argues that during and after
the Second World War this trust began to
fade. It was replaced at the urging of
statisticians and others, with a reliance on
formal statistical methods-notably the
double-blind, randomized, controlled
clinical trial as means of assessing and
improving therapeutic knowledge. A faith in
method as the motor of reform superseded
a faith in the moral qualities of individuals.
Marks is not the first to trace a shift from a
trust in people to a trust in numbers, but
his may be the strongest historical voice
arguing for the incompleteness of this
change. As advocates of clinical trials
constantly remind us today, the clinical trial
has not permeated all areas of medical
research, and most therapeutic practices
have not been subject to the probe of a
trial. It is also true that experts disagree on
the value ofparticular designs for clinical
trials, and on how to explain results.
This then is the story of an incomplete
revolution. It is grounded in detailed case
studies: (before the Second World War) the
Cooperative Clinical Group's study of
syphilis treatments, and the Commonwealth
Fund's experiment with serum treatment for
pneumonia; (during and after the War) the
National Research Council's penicillin
investigations, and the Veteran
Administration/Public Health Service
investigations of streptomycin; and (in the
1960s) the National Institutes of Health
planned Diet-Heart Study, and the
University Group Diabetes Program study
of tolbutamide. Together these examples
help to flesh out the story of this partial
revolution. They also provide an insight
into the tensions between researchers and
general practitioners, and the impact of
patient compliance on experimental design.
It is possible to quibble that the story tells
us less than we might wish to know about
the nuts-and-bolts of therapeutic testing,
and that Marks' assertion that this is a
quintessentially American tale lacks a
comparative perspective to nail the point
home. These caveats aside, Marks has
produced an important account of
twentieth-century clinical medicine;
conceptually sophisticated, and supported
by a rich lode of footnotes. The cheaper
edition of this book will ensure that future
students can afford to mine the latter at
their leisure.
David Cantor,
National Cancer Institute, Bethesda
David Dranove, The economic evolution of
American health care:from Marcus Welby to
managed care, Princeton University Press,
2000, pp. 211, $27.95 (hardback 0-691-
00693-8).
This is an economist's study of rapid
change in a trillion-dollar industry-the
healthcare business in the USA. It traces
the evolution of medical care during the
twentieth century from the traditional
doctor (as represented in the 1960s
American TV show, Marcus Welby, MD) to
the present-day managed care organization.
For the British reader, all too familiar with
the shortcomings as well as the advantages
of the National Health Service, this study of
the merits and demerits of injecting business
principles into health care is interesting and
thought-provoking. However, the author's
predilection for acronyms makes it a less
than accessible read.
Under traditional health care, David
Dranove argues that individual patients
trusted in their doctor's professional
disinterestedness, clinical competence, and
ability to co-ordinate medical services.
Physicians also had loyalty to their patients,
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